Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized-controlled study of molnupiravir in mild to moderate COVID-19 infection
ChiCTR2200059796Phase 4Recruiting
- Sponsor
- Changhai Hospital
- Start
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of molnupiravir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Changhai Hospital. Primary endpoint: Virus negative rate. Started Apr 2022; status: recruiting.
02
Drugs
molnupiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ChiCTR2200059796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200059796.